Transoral robotic surgery for salivary carcinomas of the base of tongue: a multicenter REFCOR study
- PMID: 40234274
- DOI: 10.1007/s11701-025-02332-2
Transoral robotic surgery for salivary carcinomas of the base of tongue: a multicenter REFCOR study
Abstract
Transoral robotic surgery (TORS) allows minimally invasive surgical access to the oropharynx. Its benefits are well documented for squamous cell carcinomas, but not for salivary carcinomas. The aim of this study was to describe the French experience of TORS regarding salivary gland carcinomas of the base of tongue (BOT). This was a retrospective multicentric study with a national cohort. We included all patients treated surgically for a BOT salivary gland carcinoma from January 2009 to December 2018. Descriptive analyses were performed. Among the 50 patients included, radical excision was performed through an open approach (OA; n = 33) or using TORS (n = 17). T1-T2 tumors were more common in the TORS-group (76.4% vs 60.6%), and so were low-grade tumors (58.8% vs 38.7%). Surgical margins were <1mm in 46.7% of patients in the TORS-group and 52% of patients in the OA-group. After 51.7 months of follow-up, two patients (11.8%) presented with a local recurrence in the TORS-group, versus eight patients (24.2%) in the OA-group. The rate of tracheostomy was 41.2% in the TORS-group and 63.6% in the OA-group. The rate of gastrostomy was 11.8% in the TORS-group and 36.4% in the OA-group. TORS is an acceptable minimally invasive option for selected BOT salivary carcinomas. It may provide good functional and oncological outcomes in selected cases, despite a high rate of close margins.
Keywords: Carcinoma; Glossectomy; Salivary gland neoplasms; Tongue; Transoral robotic surgery.
© 2025. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.
Conflict of interest statement
Declarations. Competing interest: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: All the clinical data needed for the study were recorded in an anonymized computerized database after approval by the local research committee under the reference number RnIPH 2023-11. This study was performed in accordance with the Declaration of Helsinki. Patient consent: Informed consent was obtained for each patient at the start of his or her care, when he or she was included in the REFCOR database.
Comment in
-
Comment on: "Transoral robotic surgery for salivary carcinomas of the base of tongue: a multicenter REFCOR study".J Robot Surg. 2025 Apr 27;19(1):178. doi: 10.1007/s11701-025-02365-7. J Robot Surg. 2025. PMID: 40287865 No abstract available.
References
-
- Devaraju R, Gantala R, Aitha H, Gotoor SG (2014) Mucoepidermoid carcinoma. BMJ Case Rep. https://doi.org/10.1136/BCR-2013-202776 - DOI - PubMed - PMC
-
- Strick MJ, Kelly C, Soames JV, McLean NR (2004) Malignant tumours of the minor salivary glands–a 20 year review. Br J Plast Surg 57:624–631. https://doi.org/10.1016/J.BJPS.2004.04.017 - DOI - PubMed
-
- Goel AN, Badran KW, Braun APG, Garrett AM, Long JL (2018) Minor salivary gland carcinoma of the oropharynx: a population-based analysis of 1426 patients. Otolaryngol Head Neck Surg 158:287–294. https://doi.org/10.1177/0194599817735309 - DOI - PubMed
-
- Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8:177–184. https://doi.org/10.1002/HED.2890080309 - DOI - PubMed
-
- Iyer NG, Kim L, Nixon IJ, Palmer F, Kraus D, Shaha AR et al (2010) Factors predicting outcome in malignant minor salivary gland tumors of the oropharynx. Arch Otolaryngol Head Neck Surg 136:1240–1247. https://doi.org/10.1001/ARCHOTO.2010.213 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical